查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
RNA 針對小分子藥物發現市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按適應症、最終用戶、地區和競爭細分
市場調查報告書
商品編碼
1348913

RNA 針對小分子藥物發現市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按適應症、最終用戶、地區和競爭細分

RNA Targeting Small Molecule Drug Discovery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Indication, By End Users, By Region and By Competition
出版日期: | 出版商: TechSci Research | 英文 173 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 RNA 標靶小分子藥物發現市場預計在預測期內將出現令人印象深刻的成長。這可以歸因於癌症、遺傳性疾病和病毒感染等疾病的日益普及以及製藥和生物技術企業研發活動支出的增加。此外，主要市場參與者的不斷增加、先進的醫療基礎設施以及研發活動投資的增加預計將在預測期內創造利潤豐厚的成長。同樣，支持新療法開發和商業化的日益完善的醫療保健系統也是多年來推動市場成長的主要因素。事實上，2020年，美國FDA核准了55種藥物，其中超過65%是小分子治療藥物。值得注意的是，這些藥物大多是傳統上針對蛋白質而開發的。

RNA 相關疾病的盛行率不斷增加

RNA 相關疾病的日益普及是全球 RNA 標靶小分子藥物發現市場成長的關鍵驅動力之一。 RNA 在各種細胞過程中發揮關鍵作用，RNA 功能失調可導致各種疾病，包括癌症、遺傳性疾病和病毒感染。這些疾病的盛行率不斷增加，導致對 RNA 標靶小分子藥物的需求不斷成長。 RNA標靶小分子藥物為治療RNA相關疾病提供了一種有前景的方法。小分子可以選擇性地結合特定的 RNA 標靶並調節其活性，為 RNA 失調引起的疾病提供潛在的治療方法。例如，RNA標靶小分子藥物在癌症治療中顯示出有希望的結果，特別是在傳統化療無效的情況下。它們還顯示出治療由 RNA 異常引起的遺傳性疾病的潛力，例如囊性纖維化。 RNA 相關疾病的日益普及導致人們越來越關注 RNA 標靶小分子藥物發現研究。許多製藥公司、新創公司和研究機構都在這一領域進行了大量投資，這正在推動市場的成長。

市場概況
預測期 2024-2028
2022 年市場規模 110104萬美元
2028 年市場規模 227669萬美元
年複合成長率 12.98%
成長最快的細分市場 製藥與生物技術公司
最大的市場 北美洲

RNA生物學的進展

RNA 生物學的進步在全球 RNA 靶向小分子藥物發現市場的成長中發揮了重要作用。隨著高通量定序和基因編輯等技術的進步，人們對 RNA 生物學的了解顯著增加。這導致了新 RNA 標靶的鑑定和新型 RNA 標靶小分子藥物的開發。 RNA 生物學的進步使研究人員能夠更好地了解 RNA 分子導致疾病的機制。這種認知導致了以前未知或知之甚少的新 RNA 靶點的鑑定。新RNA標靶的發現為藥物發現開闢了新的機遇，促進了新型RNA標靶小分子藥物的開發。此外，RNA 生物學的進步導致了用於 RNA 靶向小分子藥物發現的新技術和工具的開發。例如，高通量篩選技術的進步使研究人員能夠篩選大型化合物庫，以快速識別潛在的 RNA 標靶藥物。這加速了藥物發現過程，並使新藥的開發更有效。 RNA 生物學的進步也使得開發特異性和效力更高的 RNA 標靶小分子藥物成為可能。透過了解 RNA 分子的結構和功能，研究人員可以設計選擇性結合特定 RNA 標靶並調節其活性的小分子。

增加對 RNA 標靶藥物發現研究的資助

RNA標靶藥物發現研究資金的增加對全球RNA標靶小分子藥物發現市場的成長產生了重大影響。 RNA靶向小分子藥物為治療各種疾病提供了一種有前途的方法，包括癌症、遺傳性疾病和病毒感染。然而，開發這些藥物是一個複雜的過程，需要大量的研發投資。增加對 RNA 標靶藥物發現研究的資助有助於加速藥物發現過程並提高成功的機會。資金可支持識別和驗證 RNA 標靶、開發新篩選技術、設計小分子以及進行臨床前和臨床研究等方面的研究。此外，增加資金有助於吸引頂尖研究人員和科學家進入該領域，從而在 RNA 標靶藥物發現研究方面帶來更多創新和突破。資金的提供還可以鼓勵學術界和工業界之間的合作，從而實現更有效率和有效的藥物發現過程。包括政府、非營利組織和製藥公司在內的一些組織正在大力投資 RNA 標靶藥物發現研究。例如，美國國立衛生研究院 (NIH) 啟動了多項旨在加速 RNA 標靶藥物發現的舉措，包括以 RNA 為重點的加速藥物合作夥伴關係和藍圖神經治療網路。這些措施為該領域的研究人員提供了大量資金和資源。

對個人化醫療的需求不斷成長

對個人化醫療不斷成長的需求是全球 RNA 標靶小分子藥物發現市場成長的重要驅動力。個人化醫療旨在根據每位患者的個別特徵，考慮他們的基因組成、生活方式和環境，制定個人化的治療方案。 RNA 標靶小分子藥物為個人化醫療提供了一種有前途的方法，因為它們可以選擇性地針對與患者疾病相關的特定 RNA 分子。 RNA標靶小分子藥物可以針對個別患者的基因特徵進行設計，從而實現更有效的治療和更好的患者治療結果。例如，癌症患者的 RNA 中可能存在特定突變，導致腫瘤生長。 RNA靶向小分子藥物可以設計專門針對這種突變，從而實現更有效的治療和更少的副作用。此外，RNA標靶小分子藥物可用於治療由特定RNA異常引起的罕見疾病。這些藥物可以小批量開發和生產，使其成為個人化醫療的理想選擇。個人化醫療需求不斷成長是由多種因素推動的，包括基因組醫學的進步、患者意識的提高和對更個性化護理的需求，以及開發和製造個人化療法的技術的進步。許多製藥公司和新創公司正在投資 RNA 標靶小分子藥物發現研究，以滿足日益成長的個人化醫療需求。這些公司正在利用 RNA 生物學、高通量篩選技術和計算方法的進步來開發個人化 RNA 標靶小分子藥物。

近期發展

  • In 2021, the US FDA approved the first RNA-targeted small molecule drug, Lumasiran, for the treatment of primary hyperoxaluria type 1. Lumasiran targets and degrades the RNA that encodes the enzyme responsible for producing oxalate, which accumulates in patients with this rare genetic疾病.此次批准代表著 RNA 標靶藥物發現領域的一個重要里程碑。
  • 2020年，Alnylam Pharmaceuticals推出了美國FDA核准的首個RNA標靶小分子藥物Lumasiran。 Lumasiran 適用於治療第 1 型原發性高草酸尿症，這是一種罕見的遺傳性疾病，可導致腎臟損傷和衰竭。
  • 2019年，Alnylam Pharmaceuticals推出了Givosiran，一種RNA標靶小分子藥物，用於治療急性肝卟啉症。 Givosiran 的作用是靶向並分解 RNA，該 RNA 編碼負責在患有這種罕見遺傳疾病的患者中產生有毒血紅素中間體的酶。
  • 2021年，諾華推出了Inclisiran，一種用於治療高膽固醇的RNA標靶小分子藥物。 Inclisiran 會標靶並分解編碼 PCSK9 的 RNA，PCSK9 是一種調節血液中膽固醇水平的蛋白質。

市場區隔

全球 RNA 標靶小分子藥物發現市場可以按適應症、最終用戶、區域和競爭格局進行細分。依適應症，市場可分為癌症、傳染病、代謝性疾病、神經系統疾病等。根據最終用戶，市場可以分為製藥和生物製藥公司、學術和研究機構、其他。

市場參與者

Accent Therapeutics.、Anima Biotech Inc.、Arrakis Therapeutics.、阿斯特捷利康.、Epics Therapeutics.、Expansion Therapeutics.、Hoffmann-La Roche Ltd.、H3 Biomedicine Inc.、PTC Therapeutics.、Ribometrix.、Servier Laboratories.Skyhawk Therapeutics、 Inc. 是全球 RNA 標靶小分子藥物發現市場的一些領先參與者。

報告範圍：

在本報告中，全球 RNA 標靶小分子藥物發現市場除了詳細介紹的產業趨勢外，還分為以下幾類：

RNA 標靶小分子藥物發現市場，依適應症分類：

  • 癌症
  • 傳染性疾病
  • 代謝性疾病
  • 神經系統疾病
  • 其他

RNA 針對小分子藥物發現市場，由最終用戶提供：

  • 製藥和生物製藥公司
  • 學術及研究機構
  • 其他

RNA 標靶小分子藥物發現市場（按地區）：

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

競爭格局

公司概況：對全球 RNA 靶向小分子藥物發現市場主要公司的詳細分析。

可用的客製化：

根據給定的市場數據，TechSci Research 可根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 考慮學習的年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球 RNA 標靶小分子藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依適應症（癌症、傳染病、代謝性疾病、神經系統疾病、其他）
    • 最終用戶（製藥和生物製藥公司、學術和研究機構、其他）
    • 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
    • 按公司分類 (2022)
  • 市場地圖
    • 按指示
    • 由最終用戶
    • 按地區

第 6 章：北美 RNA 標靶小分子藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依適應症（癌症、傳染病、代謝性疾病、神經系統疾病、其他）
    • 最終用戶（製藥和生物製藥公司、學術和研究機構、其他）
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲 RNA 標靶小分子藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依適應症（癌症、傳染病、代謝性疾病、神經系統疾病、其他）
    • 最終用戶（製藥和生物製藥公司、學術和研究機構、其他）
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區 RNA 標靶小分子藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依適應症（癌症、傳染病、代謝性疾病、神經系統疾病、其他）
    • 最終用戶（製藥和生物製藥公司、學術和研究機構、其他）
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲 RNA 標靶小分子藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依適應症（癌症、傳染病、代謝性疾病、神經系統疾病、其他）
    • 最終用戶（製藥和生物製藥公司、學術和研究機構、其他）
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲 RNA 標靶小分子藥物發現市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依適應症（癌症、傳染病、代謝性疾病、神經系統疾病、其他）
    • 最終用戶（製藥和生物製藥公司、學術和研究機構、其他）
    • 按國家/地區
  • MEA：國家分析
    • 南非 RNA 標靶小分子藥物發現
    • 沙烏地阿拉伯 RNA 標靶小分子藥物發現
    • 阿拉伯聯合大公國 RNA 標靶小分子藥物發現

第 11 章：市場動態

  • 動力
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球 RNA 標靶小分子藥物發現市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 產品供應
  • 最近的發展
  • 財務（據報導）
  • 主要人員
  • SWOT分析
    • Accent Therapeutics.
    • Anima Biotech Inc.
    • Arrakis Therapeutics.
    • AstraZeneca Plc.
    • Epics Therapeutics.
    • Expansion Therapeutics.
    • F. Hoffmann-La Roche Ltd.
    • H3 Biomedicine Inc.
    • PTC Therapeutics.
    • Ribometrix.
    • Servier Laboratories.
    • Skyhawk Therapeutics, Inc.

第 16 章：策略建議

簡介目錄
Product Code: 15457

The Global RNA Targeting Small Molecule Drug Discovery Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the increasing prevalence of diseases such as cancer, genetic disorders, and viral infections and rising expenditure in R&D activities by pharmaceutical and biotechnology businesses. Also, the growing presence of key market players, advanced healthcare infrastructure, and increasing investment in research and development activities are expected to create lucrative growth during the forecast period. Similarly, a growing well-established healthcare system that supports the development and commercialization of new therapies is also a major factor fuelling the growth of the market over the years. In fact, in 2020, the USFDA approved 55 drugs, of which, over 65% were small molecule therapeutics. It is worth noting that majority of these drugs were conventionally developed to target proteins.

Increasing Prevalence of RNA-Related Diseases

The increasing prevalence of RNA-related diseases is one of the key drivers of the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. RNA plays a critical role in various cellular processes, and dysregulation of RNA function can lead to various diseases, including cancer, genetic disorders, and viral infections. The prevalence of these diseases is increasing, leading to a growing demand for RNA-targeted small molecule drugs. RNA-targeted small molecule drugs offer a promising approach for the treatment of RNA-related diseases. Small molecules can selectively bind to specific RNA targets and modulate their activity, offering a potential therapeutic approach for diseases caused by RNA dysregulation. For example, RNA-targeted small molecule drugs have shown promising results in the treatment of cancer, particularly in cases where traditional chemotherapy is not effective. They have also shown potential for the treatment of genetic disorders caused by RNA abnormalities, such as cystic fibrosis. The increasing prevalence of RNA-related diseases has led to an increased focus on RNA-targeted small molecule drug discovery research. Many pharmaceutical companies, startups, and research institutions are investing heavily in this area, which is driving the growth of the market.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 1101.04 Million
Market Size 2028USD 2276.69 Million
CAGR (2023-2028)12.98%
Fastest Growing SegmentPharmaceutical & Biotechnology Companies
Largest MarketNorth America

Advancements in RNA Biology

Advancements in RNA biology have played a significant role in the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. With the advancement of technologies, including high-throughput sequencing and gene editing, the understanding of RNA biology has increased significantly. This has led to the identification of new RNA targets and the development of novel RNA-targeted small molecule drugs. Advancements in RNA biology have enabled researchers to better understand the mechanisms by which RNA molecules contribute to disease. This understanding has led to the identification of new RNA targets that were previously unknown or poorly understood. The discovery of new RNA targets has opened up new opportunities for drug discovery, leading to the development of novel RNA-targeted small molecule drugs. Furthermore, advancements in RNA biology have led to the development of new technologies and tools for RNA-targeted small molecule drug discovery. For example, advances in high-throughput screening technologies have enabled researchers to screen large libraries of compounds to identify potential RNA-targeted drugs quickly. This has accelerated the drug discovery process and enabled the development of new drugs more efficiently. Advancements in RNA biology have also enabled the development of RNA-targeted small molecule drugs with improved specificity and potency. By understanding the structure and function of RNA molecules, researchers can design small molecules that selectively bind to specific RNA targets and modulate their activity.

Increased Funding for RNA-Targeted Drug Discovery Research

Increased funding for RNA-targeted drug discovery research has a significant impact on the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. RNA-targeted small molecule drugs offer a promising approach for the treatment of various diseases, including cancer, genetic disorders, and viral infections. However, developing these drugs is a complex process that requires significant investment in research and development. Increased funding for RNA-targeted drug discovery research can help to accelerate the drug discovery process and improve the chances of success. Funding can support research in identifying and validating RNA targets, developing new screening technologies, designing small molecules, and conducting preclinical and clinical studies. Furthermore, increased funding can help to attract top researchers and scientists to the field, leading to more innovation and breakthroughs in RNA-targeted drug discovery research. The availability of funding can also encourage collaborations between academia and industry, leading to more efficient and effective drug discovery processes. Several organizations, including governments, non-profit organizations, and pharmaceutical companies, are investing heavily in RNA-targeted drug discovery research. For example, the US National Institutes of Health (NIH) has launched several initiatives aimed at accelerating RNA-targeted drug discovery, including the RNA-focused Accelerating Medicines Partnership and the Blueprint Neurotherapeutics Network. These initiatives provide significant funding and resources for researchers working in the field.

Growing Demand for Personalized Medicine

The growing demand for personalized medicine is a significant driver of the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. Personalized medicine aims to tailor medical treatment to the individual characteristics of each patient, taking into account their genetic makeup, lifestyle, and environment. RNA-targeted small molecule drugs offer a promising approach for personalized medicine, as they can selectively target specific RNA molecules that are involved in a patient's disease. RNA-targeted small molecule drugs can be designed to be specific to individual patients' genetic profiles, leading to more effective treatments and better patient outcomes. For example, a patient with cancer may have a specific mutation in their RNA that is driving the growth of their tumor. RNA-targeted small molecule drugs can be designed to specifically target this mutation, leading to more effective treatment and fewer side effects. Furthermore, RNA-targeted small molecule drugs can be used to treat rare diseases caused by specific RNA abnormalities. These drugs can be developed and manufactured in small quantities, making them ideal for personalized medicine. The growing demand for personalized medicine is driven by several factors, including advances in genomic medicine, increasing patient awareness and demand for more personalized care, and improvements in technology for developing and manufacturing personalized therapies. Many pharmaceutical companies and startups are investing in RNA-targeted small molecule drug discovery research to meet the growing demand for personalized medicine. These companies are leveraging advancements in RNA biology, high-throughput screening technologies, and computational methods to develop personalized RNA-targeted small molecule drugs.

Rise in the Number of Startups and Small Companies Focusing on RNA-Targeted Drug Discovery

The rise in the number of startups and small companies focusing on RNA-targeted drug discovery is a significant driver of the growth of the Global RNA Targeting Small Molecule Drug Discovery Market. Startups and small companies are playing a crucial role in advancing RNA-targeted drug discovery research and bringing innovative therapies to the market. Startups and small companies are often more agile and able to quickly adopt new technologies and approaches to drug discovery. These companies can focus on niche areas of RNA biology, allowing them to identify and develop RNA targets that may have been overlooked by larger pharmaceutical companies. Furthermore, startups and small companies are increasingly receiving funding and support from venture capitalists, government agencies, and non-profit organizations. This funding allows these companies to invest in research and development and advance their pipeline of RNA-targeted small molecule drugs. The rise of startups and small companies in the RNA-targeted drug discovery space is also leading to increased competition, which is driving innovation and improving the efficiency of the drug discovery process. This competition is also leading to the development of more affordable and accessible RNA-targeted small molecule drugs, which can benefit patients globally. Several startups and small companies focusing on RNA-targeted drug discovery have already made significant advances in the field. These companies have developed innovative screening platforms, identified novel RNA targets, and advanced promising RNA-targeted small molecule drugs into preclinical and clinical trials.

Recent Development

  • In 2021, the US FDA approved the first RNA-targeted small molecule drug, Lumasiran, for the treatment of primary hyperoxaluria type 1. Lumasiran targets and degrades the RNA that encodes the enzyme responsible for producing oxalate, which accumulates in patients with this rare genetic disease. This approval represents a significant milestone for the RNA-targeted drug discovery field.
  • In 2020, Alnylam Pharmaceuticals launched Lumasiran, the first RNA-targeting small molecule drug approved by the US FDA. Lumasiran is indicated for the treatment of primary hyperoxaluria type 1, a rare genetic disorder that can lead to kidney damage and failure.
  • In 2019, Alnylam Pharmaceuticals launched Givosiran, an RNA-targeting small molecule drug for the treatment of acute hepatic porphyria. Givosiran works by targeting and degrading the RNA that encodes the enzyme responsible for producing toxic heme intermediates in patients with this rare genetic disease.
  • In 2021, Novartis launched Inclisiran, an RNA-targeting small molecule drug for the treatment of high cholesterol. Inclisiran targets and degrades the RNA that encodes for PCSK9, a protein that regulates cholesterol levels in the blood.

Market Segmentation

Global RNA Targeting Small Molecule Drug Discovery market can be segmented by Indication, End Users, Region and Competitive Landscape. Based on the indication, the market can be segmented into Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others. Based on end users, the market can be differentiated into Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others.

Market Players

Accent Therapeutics., Anima Biotech Inc., Arrakis Therapeutics., AstraZeneca., Epics Therapeutics., Expansion Therapeutics., Hoffmann-La Roche Ltd., H3 Biomedicine Inc., PTC Therapeutics., Ribometrix., Servier Laboratories., Skyhawk Therapeutics, Inc. are some of the leading players operating in the Global RNATargeting Small Molecule Drug Discovery Market.

Report Scope:

In this report, Global RNA Targeting Small Molecule Drug Discovery market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Targeting Small Molecule Drug Discovery Market, By Indication:

  • Cancer
  • Infectious Diseases
  • Metabolic Diseases
  • Neurological Diseases
  • Other

RNA Targeting Small Molecule Drug Discovery Market, By End Users:

  • Pharmaceutical and Biopharmaceutical Companies
  • Academic and Research Institutes
  • Others

RNA Targeting Small Molecule Drug Discovery Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Targeting Small Molecule Drug Discovery Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global RNA Targeting Small Molecule Drug Discovery Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
    • 5.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
    • 5.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.4. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Indication
    • 5.3.2. By End Users
    • 5.3.3. By Region

6. North America RNA Targeting Small Molecule Drug Discovery Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
    • 6.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By End User

7. Europe RNA Targeting Small Molecule Drug Discovery Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
    • 7.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By End User
    • 7.3.2. Germany RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By End User

8. Asia-Pacific RNA Targeting Small Molecule Drug Discovery Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
    • 8.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By End User
    • 8.3.2. India RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By End User

9. South America RNA Targeting Small Molecule Drug Discovery Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
    • 9.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By End User

10. Middle East and Africa RNA Targeting Small Molecule Drug Discovery Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases, Others)
    • 10.2.2. By End Users (Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, Others)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By End User
    • 10.3.3. UAE RNA Targeting Small Molecule Drug Discovery Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global RNA Targeting Small Molecule Drug Discovery Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Financials (As Reported)
  • 15.5. Key Personnel
  • 15.6. SWOT Analysis
    • 15.6.1 Accent Therapeutics.
    • 15.6.2 Anima Biotech Inc.
    • 15.6.3 Arrakis Therapeutics.
    • 15.6.4 AstraZeneca Plc.
    • 15.6.5 Epics Therapeutics.
    • 15.6.6 Expansion Therapeutics.
    • 15.6.7 F. Hoffmann-La Roche Ltd.
    • 15.6.8 H3 Biomedicine Inc.
    • 15.6.9 PTC Therapeutics.
    • 15.6.10 Ribometrix.
    • 15.6.11 Servier Laboratories.
    • 15.6.12 Skyhawk Therapeutics, Inc.

16. Strategic Recommendations